web analytics
23.7 C
Munich
Wednesday, June 29, 2022

Kontrol Energy Corp (OTCMKTS: KNRLF) Rising Fast as its BioCloud Gains Traction

Kontrol Energy Corp (OTCMKTS: KNRLF) is racing up the charts after the Company received positive lab results for BioCloud testing against the live virus that causes COVID-19. This positive result follows two successful tests against the dormant SARS-CoV-2 virus (see press release dated August 10th, 2020 and press release dated August 27th, 2020).

As the world opens backup from coronavirus technology such as the could be in huge demand. Kontrol said it has commenced discussions with two global outsource contract manufacturers who can provide Kontrol with external manufacturing capacity as Kontrol is planning for up to 20,000 BioCloud units per month as manufacturing capacity. The Company recently stated it plans to sell the BioCloud for $12,000 USD per unit.

Kontrol Energy Corp (OTCMKTS: KNRLF) operating out of Toronto, Ontario and trading as KNR in Canada and 1K8 in Frankfurt is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions. Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.

On August 5 Kontrol reported it received approval for an initial government grant of $50,000 from the National Research Council of Canada to accelerate its new Covid-19 testing technology, the Kontrol BioCloud® analyzer; a new technology designed to detect and alert for COVID-19, in real-time, through rapid on-site air sampling and detection of aerosol and droplet encapsulated viruses in indoor and outdoor environments. The BioCloud was designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.

To Find out the inside Scoop on KNRLF Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

KNRLF

Kontrol stock is on fire after the Company said it received positive lab results for BioCloud testing against the live virus that causes COVID-19. This positive result follows two successful tests against the dormant SARS-CoV-2 virus (see press release dated August 10th, 2020 and press release dated August 27th, 2020).

Kontrol will begin the commercialization process of BioCloud by initiating an application to the CSA Group. CSA is a leader in Standards Development and in Testing, Inspection and Certification around the world including Canada, the U.S., Europe and Asia. The CSA registered mark shows that a product has been independently tested and certified to meet recognized standards for safety or performance. Kontrol anticipates that a CSA approval can take from 30 to 45 days to complete and Kontrol has a history of working with CSA on various air quality and emission products. During the process of CSA approval, Kontrol will seek to establish lower detection limits of the COVID-19 virus. Lower detection limit specifications are part of the commercial specifications that Kontrol will deliver for a fully commercialized product.

Kontrol has commenced discussions with two global outsource contract manufacturers who can provide Kontrol with external manufacturing capacity. Kontrol is not making any statements or assumptions about potential revenues, however, Kontrol is planning for up to 20,000 BioCloud units per month as manufacturing capacity. This is part of Kontrol’s prudent overall planning and access to manufacturing capability.

Kontrol CEO Paul Ghezzi stated:  “We are very pleased that through a methodical approach we have been able to successfully test our technology with the live virus causing COVID-19 and will turn our focus to commercialization of BioCloud. It has been a long journey to get to this point since the initial concept design in March 2020 and through the great efforts of our team we look forward to delivering a safe space technology solution.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently running northbound Kontrol is an exciting story developing in small caps; the stock is heating up and running northbound after the Company received positive lab results for BioCloud testing against the live virus that causes COVID-19.  As the world opens backup from coronavirus technology such as the could be in huge demand. Kontrol said is has commenced discussions with two global outsource contract manufacturers who can provide Kontrol with external manufacturing capacity as Kontrol is planning for up to 20,000 BioCloud units per month as manufacturing capacity. The Company recently stated it plans to sell the BioCloud for $12,000 USD per unit. the Kontrol BioCloud® analyzer; a new technology designed to detect and alert for COVID-19, in real-time, through rapid on-site air sampling and detection of aerosol and droplet encapsulated viruses in indoor and outdoor environments. We will be updating on Kontrol when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with Kontrol.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in Kontrol either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.